Tobira Therapeutics to Present at the 31st Annual J. P. Morgan Healthcare Conference

Tobira TherapeuticsCaroline Loewy, 650-741-6625EVP & CFOorBCC Partners for Tobira TherapeuticsKaren L. Bergman, 650-575-1509Michelle Corral, 415-794-8662

Tobira Therapeutics announced today that it will be presenting at the 31 Annual J. P. Morgan Healthcare Conference in San Francisco. Andrew Hindman, Tobira’s President and CEO, will provide an overview of the company and update on recent events on Wednesday, January 9, 2013 at 11:30am.

Tobira Therapeutics is a privately held biopharmaceutical company developing innovative therapies for treatment of HIV infection. The company’s lead development candidate is cenicriviroc (CVC or TBR-652), a novel, oral, once-daily, fixed-dose combinable, dual inhibitor of chemokine receptors CCR5 and CCR2 being evaluated for the treatment of HIV infection. Tobira is currently conducting a 48-week randomized, double-blinded, double-dummy and controlled Phase 2b study of cenicriviroc in treatment-naive HIV-infected individuals with CCR5-tropic virus. Tobira plans to present twenty-four week primary analysis data from this clinical trial at a scientific meeting in the first half of 2013. Tobira has financial support from a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners. Learn more at .

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.